Metsera is a clinical-stage biopharmaceutical company developing next-generation medicines for obesity and cardiometabolic diseases. The company focuses on developing oral and injectable incretin, non-incretin, and combination therapies intended to address limitations of current GLP-1 therapies, including dosing frequency, gastrointestinal side effects, and manufacturing costs.
Metsera is publicly traded
IPO'd on January 31, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under MTSR.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2022
Employees
132
Total Funding
$505M
2 rounds
Total raised $505M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
November 2024
Amount
$215M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 2024 | Series B | $215M | — | Wellington Management, Venrock Healthcare Capital Partners |
| April 2024 | Series A | $290M | — | ARCH Venture Partners |
Whit Bernard
Founder and Chief Executive Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Viking Therapeutics
Developing oral GLP-1 receptor agonist VK2735 for obesity treatment; reported 10.9% placebo-adjusted weight loss in Phase 2 trials
Structure Therapeutics
Developing oral GLP-1 pill aleniglipron; reported >11% placebo-adjusted weight loss in Phase 2 trials
Eli Lilly
Market leader in obesity therapeutics with Mounjaro and Zepbound (tirzepatide) for diabetes and obesity
Novo Nordisk
Market leader with Ozempic, Wegovy, and developing amycretin (novel GLP-1/amylin receptor agonist) for obesity
Zealand Pharma
Developing GLP-1 and GIP agonists for metabolic and obesity-related therapeutic space
Yes, Metsera is publicly traded under the ticker symbol MTSR on the NASDAQ. The company went public in January 31, 2025.
Metsera trades under the ticker symbol MTSR on the NASDAQ. It began trading in January 31, 2025.
Metsera (MTSR on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker MTSR to place an order.
Metsera went public in January 31, 2025 via ipo. Metsera completed its IPO on January 31, 2025, raising $275M at $18 per share on the Nasdaq under ticker MTSR. The company was subsequently acquired by Pfizer in November 2025 for $65.60 per share (total enterprise value ~$7.0B) plus CVR of up to $20.65 per share.
Metsera raised $505M across 2 disclosed funding rounds prior to its public listing.
Metsera was founded by Whit Bernard in 2022.
Metsera is headquartered in New York, NY.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.